Basic Study Information
Purpose:Location: University of Rochester
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual
chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with
HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab
are monoclonal antibodies and forms of targeted therapy that attach to specific molecules
(receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab
or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are
blocked and the tumor cell may be marked for destruction by the body's immune system.
Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in
the body longer, so that these medications will have a greater effect. Hyaluronidase
also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under
the skin and shortens their administration time compared to trastuzumab or pertuzumab
alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule
agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin
is in a class of medications known as platinum-containing compounds. It works in a
way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin.
Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving
Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink
the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial
serous carcinoma or carcinosarcoma.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search